Arbutus Biopharma Corp expected to post a loss of 13 cents a share - Earnings Preview

Arbutus Biopharma

28/02/2023 14:38

* Arbutus Biopharma Corp  ABUS.OQ   ABUS.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 2. 
    * The Warminster Pennsylvania-based  company is expected to
report
 a 92.6% increase in revenue to $6.175 million from $3.21
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Arbutus Biopharma
Corp is
for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $6​, above​ its last closing price of $2.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.13       -0.13      -0.12     Beat    6.3
 Jun. 30 2022  -0.12       -0.13      -0.10     Beat    20.6
 Mar. 31 2022  -0.15       -0.16      -0.11     Beat    31.3​
 Dec. 31 2021  -0.19       -0.19      -0.15     Beat    21.1
 ​​Sep.        -0.24       -0.24      -0.24     Met     -0.8
 30 2021                                                
 Jun. 30 2021  -0.22       -0.22      -0.23     Missed  -3​
 Mar. 31 2021  -0.24       -0.23      -0.21     Beat    9.3
 Dec. 31 2020  -0.23       -0.22      -0.23     Missed  -3.9
 This summary was machine generated February 28 at 14:38 GMT. 
All figures in US dollars  unless otherwise stated